Scarica l'app Stockscreener
1.455
2.35%
-0.035
Dopo l'orario di chiusura:
1.46
0.005
+0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Ocugen Inc Borsa (OCGN) Ultime notizie
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook - Yahoo Finance
Full Transcript: Ocugen Q1 2026 Earnings Call - Sahm
Ocugen’s Convertible Debt Deal Funds a Pipeline Push, but Investors Balk at Dilution Risk - AD HOC NEWS
Ocugen Q1 2026 Earnings Call Transcript - MarketBeat
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Q1 Earnings Call Highlights - Yahoo Finance
Ocugen stock plunges after gene therapy company announces $115M debt sale - The Business Journals
OCGN cash outlook extends to 2028 as OCU400 and OCU410ST enrollment completes - Traders Union
Ocugen stock dips as Q1 losses widen - MSN
Ocugen Advances Late-Stage Gene Therapies, Bolsters Cash Runway - TipRanks
Ocugen Provides Business Update with First Quarter 2026 Financial Results - Ocugen, Inc.
Ocugen (NASDAQ: OCGN) prices $115M 2034 convertible notes deal - Stock Titan
Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes - Ocugen, Inc.
Ocugen prices $115 million convertible notes offering at 6.75% By Investing.com - Investing.com Australia
Ocugen Prices $115 Million Convertible Senior Notes Offering - marketscreener.com
Earnings call transcript: Ocugen Q1 2026 misses EPS, beats revenue - Investing.com
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Ocugen stock tumbles 17% after convertible notes offering - Investing.com
Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028 - ChartMill
Ocugen reports Q1 results, raises $115M in convertible notes - Investing.com
Ocugen reports Q1 results, raises $115M in convertible notes By Investing.com - Investing.com Canada
Ocugen, Inc. announces pricing of $115 million of 6.75% convertible senior notes - marketscreener.com
OCUGEN ($OCGN) Releases Q1 2026 Earnings - Quiver Quantitative
Ocugen: Q1 Earnings Snapshot - Barchart.com
OCGN: Strong clinical progress and extended cash runway position the pipeline for key regulatory milestones - TradingView
Ocugen says two blindness gene therapy trials are fully enrolled - Stock Titan
Ocugen prices $115 million convertible notes offering at 6.75% - Investing.com
Ocugen, Inc. Announces Pricing Of $115 Million Of 6.75% Convertible Senior Notes - TradingView
Q1 2026 Ocugen Inc Earnings Call Transcript - GuruFocus
Ocugen, Inc. Announces Pricing of $115 Million Convertible Senior Notes Offering - Quiver Quantitative
Ocugen's $115M note deal sends $32.7M to repay Avenue loan - Stock Titan
Ocugen plans $115 million convertible notes offering By Investing.com - Investing.com South Africa
MSN Money - MSN
Ocugen’s $115 Million Convertible Play Buys Time for a Pivotal Pipeline Push - AD HOC NEWS
symbol__ Stock Quote Price and Forecast - CNN
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes - Ocugen, Inc.
Ocugen (OCGN) Plans $115 Million Private Offering of Convertible Notes - GuruFocus
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen Announces Private Convertible Notes Offering to Deleverage - TipRanks
Ocugen issues $115M notes to repay debt; stock faces after-hours selling - MSN
Ocugen plans $115 million convertible notes offering - Investing.com
Ocugen (NASDAQ: OCGN) to issue $115M convertibles and repay Avenue loan - Stock Titan
OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen (OCGN) Completes Enrollment for Phase 2/3 Pivotal Trial of OCU410ST Gene Therapy - Insider Monkey
Ocugen (OCGN) Expected to Announce Earnings on Friday - MarketBeat
Ocugen’s Gene Therapy Trio Nears the Regulatory Finish Line - AD HOC NEWS
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
OCGN gene therapy pipeline: Key 2026-27 catalysts ahead - MSN
Ocugen’s $10 Price Target Hangs on a Tightrope of Clinical Data and Cash - AD HOC NEWS
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Earnings Preview: Ocugen to Report Financial Results Pre-market on May 05 - Moomoo
Ocugen (OCGN) up 2.9% since last earnings report: Can it continue? - MSN
Ocugen (OCGN) price target increased by 11.43% to 11.37 - MSN
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):